We came across a bullish thesis on CureVac N.V. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CVAC. CureVac N.V.’s share was trading at $5.20 as of December 1st. CVAC’s trailing and forward P/E were 8.30 and 5.24 respectively according to Yahoo Finance.
Pixabay/Public Domain
CureVac (CVAC) represents the most credible non-U.S. mRNA platform positioned for “toll-road” economics through foundational IP and process know-how that others may...
